NPC-Exosome Carry Wild and Mutant-type p53 among Nasopharyngeal Cancer Patients
Abstract
BACKGROUND: Nasopharyngeal cancer (NPC) is known to release a specific exosome. NPC-derived exosome (NPC-Exo) could carry p53. However, information regarding the type of p53 carrier on NPC-Exo remains limited. This study aims to introduce our important findings regarding the type of p53 NPC-Exo cargo.
METHODS: Serum from patients with NPC were prepared for exosome isolation with Seramir Exoquick by following the manual instructions. RT-PCR was conducted to determine the expression levels of latent membrane protein 1 (LMP-1) and p53 in the exosome isolate. Partial sequencing of p53 amplicon was conducted to determine mutation type of p53.
RESULTS: There were 8 patients enrolled in this study. According to RT-PCR results, the expression levels of LMP-1 and p53 varied in the NPC-Exo isolate. Based on sequencing analysis, 1 case of p53 mutation was noticeable.
CONCLUSION: According to current results, the NPC-derived exosome potentially carries not only wild type but also mutant type p53. Further research is needed to explore deeper the effect of the mutant type p53 as an exosome carrier in the clinical application.
KEYWORDS: Nasopharyngeal cancer, exosome, p53, mutation
Full Text:
PDFReferences
Kurniawan A, Risanti ED, Suhda S, Rinonce HT, Dwianingsih EK, Fachiroh J. Wnt inhibitory factor 1 (WIF1) qualitative-methylation from peripheral blood could not be used as biomarker for the risk of nasopharyngeal carcinoma or smoking behavior in yogyakarta panel. Indones Biomed J. 2019; 11: 273-8, CrossRef.
Risanti ED, Kurniawan A, Wahyuningsih L, Dwianingsih EK, Rinonce HT, Fachiroh J. Association of peripheral blood RASSF1A and CDKN2A methylation status with smoking behaviour in nasopharyngeal carcinoma. Indones Biomed J. 2018; 10: 123-7, CrossRef.
Shield KD, Ferlay J, Jemal A, Sankaranarayanan R. The global incidence of lip , oral cavity , and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017; 67: 51-64, CrossRef.
Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, Incidence, sign, and symptoms at presentation. Chin J Cancer. 2012; 31: 185-96, CrossRef.
Kuhuwael FG, Perkasa MF, Miskad UA, Punagi AQ, Said FA. Comparison of the means of argyrophilic nucleolar organizer region (mAgNOR) pre- and post-therapy in nasopharyngeal carcinoma patients at Wahidin Sudirohusodo General Hospital Makassar. Indones Biomed J. 2016; 8: 103-8, CrossRef.
Zhou Y, Xia L, Lin J, Wang H, Oyang L, Tan S, et al. Exosomes in nasopharyngeal carcinoma. J Cancer. 2018; 9: 767-77, CrossRef.
Ye S, Li ZL, Luo D, Huang B, Chen YS, Zhang X, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014; 5: 5439-52, CrossRef.
Chan YK, Zhang H, Liu P, Tsao SW, Lung ML, Mak NK, et al. Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. Int J Cancer. 2015; 137: 1830-41, CrossRef.
Kadriyan H, Yudhanto D, Djannah F, Aryani IGAT, Sulaksana MA. Correlation of cancer stage with expression of LMP-1 and BCL-2 in patients with undifferentiated nasopharyngeal cancer. ASM Sci J. 2021; 14: 33-8, article.
Burdakov VS, Kovalev RA, Pantina RA, Varfolomeeva EY, Makarov EM, Filatov MV. Exosomes transfer p53 between cells and can suppress growth and proliferation of p53-negative cells. Cell Tissue Biol. 2018; 12: 20-6, CrossRef.
Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019; 11: 284-92, CrossRef.
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000; 60: 6788-93, PMID.
Liu J, Liu Y, Zhang Z, Sun H, Ji X, Li B, et al. Prognostic value of the Epstein–Barr virus and tumor suppressor gene p53 gene in nasopharyngeal squamous cell carcinoma. J Cancer Res Ther. 2019; 15: 426-36, CrossRef.
Zihlif MA, Mahmoud IS, Ghanim MT, Zreikat MS, Alrabadi N, Imraish A, et al. Thymoquinone efficiently inhibits the survival of EBV-infected B cells and alters EBV gene expression. Integr Cancer Ther. 2013; 12: 257-63, CrossRef.
Chakrani F, Armand JP, Lenoir G, Ju LY, Liang JP, May E, et al. Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from Southeastern Asia. Int J Cancer. 1995; 61: 316-20, CrossRef.
Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012; 40: e115, CrossRef.
Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquère S, Nishi N, Hirashima M, et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9. BMC Cancer. 2006; 6: 283, CrossRef.
Li M, Zeringer E, Barta T, Schageman J, Cheng A, Vlassov AV, et al. Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philosopical Trans R Soc B. 2014; 369: 20130502, CrossRef.
Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, et al. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncol Lett. 2015; 9: 113-8, CrossRef.
Martin ACR, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002; 19: 149-64, CrossRef.
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat. 2002; 19: 607-14, CrossRef.
Qin ZQ, Li QG, Yi H, Lu SS, Huang W, Rong ZX, et al. Heterozygous p53-R280T mutation enhances the oncogenicity of NPC cells through activating PI3K-Akt signaling pathway. Front Oncol. 2020;10: 104, CrossRef.
Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018; 9: 771, CrossRef.
Ren J, He W, Zheng L, Duan H. From structures to functions: Insights into exosomes as promising drug delivery vehicles. Biomater Sci. 2016; 4: 910-21, CrossRef.
Trivedi M, Talekar M, Shah P, Ouyang Q, Amiji M. Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization. Oncogenesis. 2016; 5: e250-12, CrossRef.
Pavlakis E, Neumann M, Stiewe T. Extracellular vesicles : messengers of p53 in tumor – stroma communication and cancer metastasis. Int J Mol Sci. 2020; 21: 9648, CrossRef.
König L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, et al. Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. Oncoimmunology. 2018; 7: e1376153, CrossRef.
Yang JK, Song J, Huo HR, Zhao YL, Zhang GY, Zhao ZM, et al. DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme. Ther Adv Med Oncol. 2017; 9: 741-54, CrossRef.
DOI: https://doi.org/10.18585/inabj.v13i4.1718
Copyright (c) 2021 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
